VANCOUVER, March 28 /CNW/ - Protox(TM) Therapeutics Inc. (TSX-V:PRX)
announced today that it has initiated a Phase 1 clinical study of PRX302 for
the treatment of benign prostatic hyperplasia (BPH, commonly known as enlarged
prostate) at two Canadian sites.
